Log inSign up
Reading a stock page
  • The tabs show the price chart, results, shareholding, events and news for this one company.
  • The Signal Score sums up trend, momentum and quality from past data. It is a description, not a forecast.
  • Every figure names its source. "Official" means it came from NSE or BSE filings.
  • Use the star to watch the stock, or Add to portfolio to record a trade.

Prices during market hours are delayed by up to 15 minutes. Nothing here is a recommendation to buy or sell.

« Dashboard

ASTRAZEN ☆ BSE also on NSE

ASTRAZENECA PHARMA INDIA LTD. · code 506820 · INE203A01020 · Pharma & Healthcare · series A · Daily price history

6,120.45 +113.50 (+1.89%) close on 19 Nov 2026
Official NSE & BSE Auto-Sync: Checking Overview, Financials, Technicals, Shareholding & Events in the background...
43

ISA Signal Score: Weak

Caution: avoid adding, review holdings. Based on prices to 2026-11-19. Confidence 100%.

Trend0
Momentum31
52-week range12
Volume69
Risk64
Fundamentals91

Working for it

  • Profit grew 63% year on year
  • Revenue grew 29% year on year
  • Low debt

Working against it

  • Price is below its 20-day average
  • Price is below its 50-day average
  • Price is below its 200-day average (long-term weakness)
  • 50-day average is below the 200-day average
  • 50-day average is falling
  • MACD is negative and weakening

Red flags

  • Thinly traded: average daily turnover is low, so entering or exiting can be hard

Measured reference levels (not forecasts): 20-day low 5,988.15, 52-week high 9,287.15, typical daily move 221.69, two typical moves below price 5,677.07.

A rule-based reading of price, volume and filed numbers. It is information, not investment advice, and it can be wrong. Do your own research.

At a glance

Five quick readings from results and prices. A starting point for your own research, not advice.
QualityStrongROE 24.8%, ROCE 33.4%, almost no debt
GrowthNot knownNeeds at least 3 years of results. More years load on later visits.
ValuationExpensiveP/E 94.7 vs sector median 44.6, 21.5x book
MomentumWeakBelow its 200-day average, lagged NIFTY 50 by 30.8 points
RiskLowSwings 23% a year, fell up to 38% from a peak, beta 0.56

Smart Investor Tips: ASTRAZEN

Balanced / Watch for Key Level Confirmation

Actionable Insights & Positives

  • Strong earnings compounding: net profit grew at 62.7% CAGR over 1 years.
  • High capital efficiency: ROE of 24.8% indicates strong returns on shareholder equity.
  • Tip: Click the star button above to add this stock to your Watchlist and set a target "Buy below" alert price.

Risk Checks & Things to Verify

  • Long-term downtrend: price is below its 200-day average (Rs 7,786.92). Wait for a base formation and reclaim of the 50-day average (Rs 6,295.64) before committing fresh capital.
  • Premium valuation: P/E of 94.7x vs sector median 44.6x leaves less margin of safety if growth slows.

BSE Authentic Bhavcopy & Cross-Exchange Check No API Key

Runs authentic BSE price & volume verification (latest BSE Bhavcopy snapshot, split-adjusted 52W High/Low, 20/50/200 DMA alignment, and 20-day volume trend, plus cross-listed NSE MCP check when shared by ISIN).

Algorithmic Momentum Prediction & Optimal Entry PriceHOLD / POSITIVE ON SUPPORT (Score 64/100)

Consolidating. If buying, accumulate only on dips into support at Rs 5,660.00 – Rs 6,120.45 (Ideal ~Rs 5,890.23). Review if price closes below Rs 5,327.47; upside resistance near Rs 6,903.20.

Optimal Support areaTranche 1 (50%)Tranche 2 (50%)Risk level / ReviewLevel 1 (Swing)Level 2 (Breakout)Risk : Reward
Rs 5,660.00 – Rs 6,120.45
Ideal ~Rs 5,890.23
Rs 6,120.45 Rs 5,660.00 Rs 5,327.47
ATR 3.6%
Rs 6,903.20 Rs 9,449.00 1 : 1.8
RSI 44 · Vol 1.47x
1M 3M 6M 1Y 3Y ALL Investment checklist Download CSV 3M change -20.0% · high 7,750.70 · low 5,660.00 · max drawdown -25.4%

Live Candlestick & TradingView Chart (ASTRAZEN)

MARKET CLOSED - EOD SNAPSHOT
Style:  Timeframe:  Overlays:

Key figures results FY24 standalone, price 19 Nov

P/E94.7sector median 44.6
P/B21.49xprice / book value
EPSRs 64.60grew 62.6% a year
Dividend yield-from saved dividend events
Debt to equity0.00xmore cash than debt
Sales growth29.2%a year over 1 years
Profit growth62.7%a year over 1 years
Operating margin15.5%net margin 12.5%

From the official NSE results filings, standalone. P/E uses the last full year's EPS, PEG 1.51, EV/EBITDA 73.7. See all years.

Company Debt, Borrowings & Cash Flow Health (Official FY24 Standalone Filing)

Auto-extracted from official NSE/BSE XBRL Balance Sheet & Cash Flow statements (Rs Crore).

Strong Balance Sheet & Cash Flow · Score 87/100
Total Debt / Loans Rs 0 Cr Reduced Rs 0 Cr YoY
Cash & Bank Balances Rs 506 Cr Liquid cash & equivalents
Net Debt (Loans − Cash) Net Cash Rs 506 Cr Debt-free on net basis
Debt to Equity & Interest Cover 0.00x D/E Interest cover: 184.0x EBIT
Operating Cash Flow (OCF) Rs 92.5 Cr OCF/PAT conversion: 57%
Free Cash Flow (FCF) Rs 81.8 Cr After Capex of Rs 10.8 Cr
  • Net Cash / Debt-Free balance sheet (Cash Rs 506 Cr exceeds Total Loans Rs 0 Cr).
  • Strong loan interest coverage (184.0x EBIT/Interest).
  • Positive Free Cash Flow (Rs 81.8 Cr after Capex) available for debt reduction & dividends.

About ASTRAZENECA PHARMA INDIA

No company description saved yet. Use Profile below to read about this company.

Listed on BSE NSE

Market capNot available
First listed04 May 2001BSE not available · NSE 04 May 2001
Face valueRs 2
Book valueNot available
ROENot availableReturn on equity
ROCENot availableReturn on capital employed

NSE: listing date, face value

Profile completeness2 of 8Missing: description, industry, share count, book value, ROE, ROCE

Not checked yet.

Profile, History and Financial records open a web search for this company in a new tab.

Shareholding

Promoters and group 75.00% 0.00 pp, public 25.00%, as on 30 Sep 2026. Holder names and history

Day range5,990.00 to 6,154.75Open 6,046.00
52-week high9,255.00 -33.9% from high (08 Dec 2025)
52-week low5,660.00 +8.1% from low (09 Oct 2026)
Volume631 1.1x the 20-day average
RSI (14)45 neutral
Volatility (30d)29.6%annualised
5,660.00
9,255.00

Returns

1W-4.8%
1M+1.3%
3M-18.4%
6M-28.7%
1Y-32.9%
YTD-32.1%
3Y a year+9.6%
5Y a year+14.6%

Against the NIFTY 50

PeriodASTRAZENNIFTY 50Difference
1M+1.3%+11.5% -10.2 pts
3M-18.4%+5.3% -23.7 pts
6M-28.7%+7.9% -36.5 pts
1Y-32.9%-2.1% -30.8 pts

Risk over the past year

Volatility23%low
Deepest fall-38.1%from a peak
Beta0.56moves less than the index
Best day+5.1%13 Apr 2026
Worst day-6.1%13 Nov 2026
Up days45%of sessions

Returns use closing prices. Bonus issues and splits are adjusted automatically when detected. Beta compares daily moves with the NIFTY 50 over 246 shared sessions.

AI analysis

Company turnover, products, risks and entry ideas, written by the AI provider you set up in Settings.

Open AI analysis

🛡 Forensic Financial Health: Piotroski F-Score & 3-Step DuPont ROE Decomposition

Institutional balance-sheet quality, earnings-to-cash conversion, and ROE driver breakdown from official XBRL filings.

Piotroski F-Score: 8 / 9 · Fortress Balance Sheet
3-Step DuPont ROE Identity: High Asset-Velocity & Turnover Compounder
Net Margin: 12.5% × Asset Turnover: 1.20x × Equity Multiplier: 1.51x = ROE 24.8%
✓ Positive Net Profit (PAT > 0) Rs 162 Cr
✓ Positive Operating Cash Flow (OCF > 0) Rs 92.5 Cr
⚠ High Cash Conversion (OCF >= 85% of PAT) 57% conversion
✓ Improving Return on Assets (ROA YoY) 15.0% vs 10.1%
✓ Conservative / Decreasing Debt-to-Equity 0.00x (prev 0.00x)
✓ Healthy Balance Sheet Asset Coverage 3.02x
✓ Institutional Return on Equity (ROE >= 14%) 24.8%
✓ Stable / Expanding Profit Margin YoY 12.5% vs 9.9%
✓ Asset Turnover Efficiency (Sales / Assets) 1.20x

Quarterly Results (Last 5 Quarters — QoQ & YoY Acceleration) Rs crore

Rs crore Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024
Sales / Revenue 306383388408440
Sales QoQ % -+25.3%+1.1%+5.3%+7.9%
Operating Profit 15.149.4-19.552.543.4
Operating Margin (OPM %) 4.9%12.9%-5.0%12.9%9.9%
Net Profit (PAT) 15.839.5-11.838.430.9
Profit QoQ % -+149.9%-129.9%+426.0%-19.7%
Profit YoY % ----+95.3%
Net Margin % 5.2%10.3%-3.0%9.4%7.0%

Sales and profit Rs crore, standalone

Sales growth+29.2%a year, 1Y
Profit growth+62.7%a year, 1Y
EPS growth+62.6%a year, 1Y
Avg ROE20.9%2 years

Profit and loss

Rs croreFY23FY24
Sales1,0031,296
Sales growth-+29.2%
Operating profit125201
Operating margin12.5%15.5%
Other income26.134.8
Interest0.631.20
Depreciation16.314.9
Profit before tax134220
Tax rate26.0%26.4%
Net profit99.3162
Profit growth-+62.7%
Net margin9.9%12.5%
EPS (Rs)39.7264.60

Balance sheet

Rs croreFY23FY24
Equity (net worth)589712
Borrowings00
Cash500506
Total assets9851,078
Debt to equity0.00x0.00x

Debt, Loans, Cash Flow & Working Capital

Rs croreFY23FY24
Operating Cash Flow (OCF)58.392.5
Capital Expenditure (Capex)8.5210.8
Free Cash Flow (FCF = OCF - Capex)49.881.8
OCF / Net Profit Conversion0.59x0.57x
Total Borrowings / Loans00
Cash & Bank Balances500506
Trade Receivables (Cr)108153
Receivable Days39.13x43.14x
Inventories (Cr)190228
Inventory Days69.22x64.20x

Returns on capital

Rs croreFY23FY24
ROE16.9%24.8%
ROCE22.4%33.4%
Interest cover213.86x183.95x

Read from the official annual results filed with NSE (XBRL), standalone figures. ROE uses average equity of the year and the year before when both are saved, ROCE uses profit before interest and tax over total assets less current liabilities. EPS is per today's share. More years are loading and will appear on a later visit. Check the annual report before investing.

Compared with its sector Pharma & Healthcare

StockPriceDay1 yearMkt cap (Cr)P/EP/BROENet margin
ALIVUSALIVUS LIFE SCIENCES LIMITED 1,449.85 +0.3% - 17,768 37.7 7.6 20.2% 20.6%
CAPLIPOINTCAPLIN POINT LABORATORIES LTD. 2,085.40 -0.0% - 15,839 34.6 6.8 19.7% 27.0%
ASTRAZENASTRAZENECA PHARMA INDIA LTD. 6,120.45 +1.9% - 15,301 94.7 21.5 22.7% 12.5%
AARTIPHARMAarti Pharmalabs Limited 1,024.80 +1.3% - 9,287 42.8 5.3 12.3% 11.7%
BLUEJETBlue Jet Healthcare Limited 516.80 -0.2% - 8,964 54.7 10.6 19.4% 23.0%
CIPLACIPLA LTD. 1,416.00 -0.3% - - 29.5 - - 13.7%
ALKEMAlkem Laboratories Limited 5,145.00 -1.1% - - 26.7 - 17.0% 16.0%
DIVISLABDIVIS LABORATORIES LTD. 11,178.00 +1.0% - - 115.6 - 15.3% 24.3%
WOCKPHARMAWOCKHARDT LTD. 2,186.60 +7.9% - - - - - -
RUBICONRUBICON RESEARCH LIMITED 1,726.00 +3.9% - - - - - -
APOLLOHOSPAPOLLO HOSPITALS ENTERPRISE LT 8,744.80 -0.8% - - 64.8 - 21.1% 7.9%
RAINBOWRainbow Children's Medicare Li 1,241.45 -1.3% - - - - - -
Sector median- 44.67.617.0%

The 12 largest of 80 stocks in this sector on BSE, by market cap where known and traded value otherwise. Valuation shows for stocks whose results this site has read; it fills in as people open more stock pages. Prices from 19 Nov 2026.

Today: 15 minute chart and signal

Opens when you view this tab.

Analysis and next-session reading

Opens when you view this tab.

Complete analysis report Financials, shareholding, events, risks and a data reliability score.

Signals

Price is below its 50-day average 20-day average is below the 50-day (short-term downtrend) Price is below its 200-day average (long-term downtrend) RSI 45: neutral

Simple rules applied to end-of-day prices. They describe what the chart is doing and are not advice to buy or sell.

When is a good price? from this stock's own price history

The price is in the lower quarter of its 1-year range and is lower than it was on 91% of days in the past year.

Support (prices below today's)

20-day low5,860.00-4.3%
60-day low5,660.00-7.5%
52-week low5,660.00-7.5%

Resistance (prices above today's)

50-day average6,295.64+2.9%
20-day high6,800.00+11.1%
60-day high7,449.70+21.7%
200-day average7,786.92+27.2%

Zones buyers often watch

Lower quarter of the 1-year range 5,660.00 to 6,558.75 price is inside this zone now
Pullback of 10% to 20% from the high 7,404.00 to 8,329.50 A common area for dips inside an uptrend.
Around the 200-day average 7,553.32 to 8,020.53 Long-term trend line, often watched as support.

Deepest fall from a peak in the past year: -38.1%. Currently -33.6% below its latest peak. Levels are from history and do not predict where the price will go.

Moving averages and momentum

IndicatorValueReading
20-day average6,231.32 Price is 1.8% below
50-day average6,295.64 Price is 2.8% below
200-day average7,786.92 Price is 21.4% below
RSI (14)45Neutral
MACD (12, 26, 9)-40.14Below its signal line (momentum fading)
Volatility (30d)29.6%Medium yearly swings

Support and resistance

R26,253.15
R16,186.80
Pivot6,088.40
S16,022.05
S25,923.65

Classic pivot levels from the latest session's high, low and close. Prices often pause near them, but they are only reference points.

DateOpenHighLow CloseChangeVolume
2026-11-19 6,046.00 6,154.75 5,990.00 6,120.45 +1.89% 631
2026-11-18 6,155.05 6,389.00 5,967.95 6,006.95 -2.58% 692
2026-11-17 6,020.05 6,200.00 5,970.00 6,166.20 +2.21% 394
2026-11-16 6,038.05 6,070.00 5,910.00 6,032.75 -0.10% 1,160
2026-11-13 6,399.05 6,399.05 6,000.00 6,039.00 -6.10% 1,003
2026-11-12 6,537.05 6,548.75 6,420.00 6,431.20 -1.23% 497
2026-11-11 6,589.40 6,605.80 6,480.70 6,511.10 -0.02% 205
2026-11-09 6,499.25 6,540.35 6,392.90 6,512.20 +0.50% 545
2026-11-06 6,308.15 6,800.00 6,290.45 6,387.90 +1.48% 2,792
2026-11-05 6,532.95 6,532.95 6,205.00 6,294.90 -1.10% 180
2026-11-04 6,350.00 6,399.00 6,350.00 6,365.10 +0.39% 172
2026-11-03 6,319.00 6,353.55 6,295.30 6,340.60 +0.91% 104
2026-11-02 6,383.25 6,445.95 6,255.00 6,283.25 -1.32% 396
2026-10-30 6,257.50 6,383.20 6,250.00 6,367.35 +1.10% 119
2026-10-29 6,190.05 6,319.95 6,161.00 6,298.05 +1.02% 410
2026-10-28 6,058.50 6,385.00 6,058.50 6,234.70 +2.66% 1,034
2026-10-27 6,005.05 6,100.00 5,995.00 6,073.10 -0.03% 120
2026-10-26 6,039.10 6,112.80 5,890.30 6,074.75 +1.45% 266
2026-10-23 6,035.20 6,035.20 5,860.00 5,988.15 -1.81% 288
2026-10-22 6,068.05 6,124.00 6,000.00 6,098.65 +0.36% 199
2026-10-21 6,011.05 6,130.85 5,971.20 6,076.90 +0.56% 1,073
2026-10-19 5,925.00 6,078.40 5,850.00 6,043.30 +1.29% 177
2026-10-16 5,930.00 5,985.10 5,860.50 5,966.05 +0.73% 117
2026-10-15 5,900.65 6,000.00 5,879.30 5,922.60 -0.35% 292
2026-10-14 5,850.05 5,955.00 5,839.00 5,943.50 +0.96% 299
2026-10-13 5,920.00 5,932.75 5,800.00 5,887.00 -0.57% 460
2026-10-12 5,860.05 5,930.85 5,833.95 5,920.60 +1.52% 152
2026-10-09 5,726.00 5,860.50 5,660.00 5,831.85 +2.24% 727
2026-10-08 5,918.60 5,918.60 5,669.10 5,704.05 -3.62% 842
2026-10-07 6,019.50 6,019.50 5,805.00 5,918.55 -1.08% 826
2026-10-06 5,913.05 5,994.80 5,888.25 5,983.25 +1.19% 474
2026-10-05 6,078.15 6,087.30 5,889.10 5,913.00 -1.95% 269
2026-10-01 6,133.00 6,154.05 5,977.60 6,030.45 -2.56% 995
2026-09-30 6,225.65 6,280.00 6,130.00 6,188.75 -1.05% 593
2026-09-29 6,308.25 6,350.00 6,217.50 6,254.35 -0.53% 403
2026-09-28 6,490.85 6,490.85 6,267.25 6,287.50 -3.53% 912
2026-09-25 6,600.00 6,661.00 6,444.00 6,517.85 -1.08% 969
2026-09-24 6,678.80 6,701.00 6,562.75 6,588.90 -1.79% 466
2026-09-23 6,685.55 6,730.00 6,650.05 6,709.20 -0.04% 341
2026-09-22 6,663.90 6,742.00 6,606.30 6,712.15 +0.72% 342
2026-09-21 6,709.80 6,784.00 6,624.00 6,663.90 -1.30% 128
2026-09-18 6,610.00 6,772.65 6,610.00 6,751.40 +1.15% 402
2026-09-17 6,710.80 6,719.90 6,650.15 6,674.55 -0.54% 249
2026-09-16 6,751.00 6,881.65 6,656.30 6,710.80 +0.26% 541
2026-09-15 6,736.00 6,790.50 6,621.00 6,693.35 -1.36% 1,195
2026-09-11 6,858.70 6,858.70 6,760.90 6,785.35 -1.07% 463
2026-09-10 6,900.00 6,900.00 6,842.80 6,858.65 -0.59% 172
2026-09-09 6,864.80 6,914.80 6,810.00 6,899.30 +0.50% 482
2026-09-08 6,860.05 6,933.45 6,827.35 6,864.80 +0.16% 642
2026-09-07 6,917.00 6,964.60 6,815.30 6,853.70 -1.11% 473
2026-09-04 6,940.00 7,060.00 6,901.20 6,930.80 -0.23% 784
2026-09-03 6,854.50 6,975.05 6,850.05 6,946.95 +1.12% 516
2026-09-02 6,885.00 6,895.00 6,832.15 6,870.25 -0.82% 646
2026-09-01 6,900.10 7,024.95 6,900.10 6,927.10 -0.63% 376
2026-08-31 7,050.00 7,100.00 6,905.00 6,970.75 -1.91% 371
2026-08-28 7,131.60 7,158.25 7,081.00 7,106.25 -0.21% 139
2026-08-27 7,155.45 7,196.00 7,075.00 7,121.10 -0.48% 617
2026-08-26 7,230.00 7,245.45 7,140.00 7,155.45 -0.15% 431
2026-08-25 7,298.55 7,298.55 7,120.00 7,166.30 -0.74% 747
2026-08-24 7,400.05 7,449.70 7,194.05 7,220.05 -2.57% 1,697
2026-08-21 7,580.50 7,580.50 7,380.00 7,410.50 -1.25% 576
2026-08-20 7,519.45 7,613.00 7,480.20 7,504.30 -0.05% 508
2026-08-19 7,610.25 7,648.95 7,490.00 7,508.20 -1.85% 533
2026-08-18 7,680.85 7,750.70 7,595.00 7,649.85 +0.28% 144

News from the last 15 days More

Shareholding pattern

Up to dateNSE listingChecks passed

Quarter ended 30 Sep 2026, filed 16 Oct 2026. Latest filing is for the expected quarter (Sep 2026). Company: ASTRAZENECA PHARMA IND LT, ISIN INE203A01020.

Promoters and group
75.00%
0.00 pp vs Jun 2026
Public (all, Category B)
25.00%
0.00 pp vs Jun 2026

Foreign, domestic institution and mutual fund lines need the filing file for the period. An admin can load them under Admin > Shareholding tracker.

Ownership split

Trend

Latest quarter compared

CategoryPrevious (Jun 26)Latest (Sep 26)Change (pp)Change in sharesYear earlier (pp)What it may mean
Promoters and group75.00%75.00%0.00 pp-0.00 ppNo material change.
Public (all, Category B)25.00%25.00%0.00 pp-0.00 ppNo material change.

Change is in percentage points (latest percent minus previous percent), not a relative change. Mutual funds and insurers are part of domestic institutions and are never added to it. Only comparable quarters (1 to 6 months apart; about a year for the year-earlier column) are compared.

Insights and risk alerts

No rule was triggered by the data in the database. That is not a clean bill of health: the rules look only at reported holdings.

These alerts describe reported ownership. They are not buy or sell advice. Judge the company with its results, debt, valuation and announcements.

Who holds the shares

The exchange listing has no filing file for this stock, so holder names are not available.

Quarter by quarter

Quarter endedPromotersChangePublicChangeFiledSource
Sep 202675.00%0.00 pp25.00%0.00 pp16 Oct 2026NSE
Jun 202675.00%0.00 pp25.00%0.00 pp20 Jul 2026NSE
Mar 202675.00%0.00 pp25.00%0.00 pp20 Apr 2026NSE
Dec 202575.00%0.00 pp25.00%0.00 pp20 Jan 2026NSE
Sep 202575.00%0.00 pp25.00%0.00 pp19 Oct 2025NSE
Jun 202575.00%0.00 pp25.00%0.00 pp21 Jul 2025NSE
Mar 202575.00%0.00 pp25.00%0.00 pp20 Apr 2025NSE
Dec 202475.00%0.00 pp25.00%0.00 pp20 Jan 2025NSE
Sep 202475.00%0.00 pp25.00%0.00 pp18 Oct 2024NSE
Jun 202475.00%0.00 pp25.00%0.00 pp18 Jul 2024NSE
Mar 2024 revised75.00%0.00 pp25.00%0.00 pp15 Apr 2024NSE
Dec 202375.00%0.00 pp25.00%0.00 pp16 Jan 2024NSE
Sep 202375.00%0.00 pp25.00%0.00 pp17 Oct 2023NSE
Jun 202375.00%0.00 pp25.00%0.00 pp19 Jul 2023NSE
Mar 202375.00%0.00 pp25.00%0.00 pp17 Apr 2023NSE
Dec 202275.00%0.00 pp25.00%0.00 pp14 Jan 2023NSE
Sep 202275.00%0.00 pp25.00%0.00 pp18 Oct 2022NSE
Jun 202275.00%0.00 pp25.00%0.00 pp20 Jul 2022NSE
Mar 202275.00%0.00 pp25.00%0.00 pp20 Apr 2022NSE
Dec 202175.00%0.00 pp25.00%0.00 pp20 Jan 2022NSE
Sep 202175.00%-25.00%-13 Oct 2021NSE
Shareholding details

Loading...

Events

Not checked yet

BSE events come from the BSE corporate actions file, which an admin uploads. There is no automatic BSE fetch. Nothing has been imported for this stock yet.

No events saved for this stock yet.

Fetched from NSE automatically and saved on this site, so past events stay available. Ex date is the first day the stock trades without the benefit; a bonus or split is applied to old prices on its own from that day. Confirm on the exchange website before acting.

ISA shows information and signals worked out from past prices and company filings. They are not recommendations to buy, sell or hold any security, and ISA is not a SEBI-registered investment adviser or research analyst. Prices may be delayed. Check with a registered adviser before you invest.